Perrigo agrees to sell rare disease unit to Esteve for €275 million
MADRID, May 17 (Reuters) - Spanish pharmaceuticals company Esteve has agreed to sell a 26% stake to German private investment firm Lubea, which will become a strategic partner, the family-owned firm based in Barcelona said in a statement on Wednesday.
Esteve Pharmaceuticals` Thiotepa Riemser (Thiotepa) Approved In Europe
BARCELONA, Spain, May 3, 2021 /PRNewswire/ -- Esteve Pharmaceuticals (ESTEVE), an international specialty pharmaceutical company devoted to the development and commercialization of innovative products, today announced an agreement with Kowa Pharmaceuticals America, Inc. (KPA) under which ESTEVE has granted KPA exclusive rights to commercialize E-58425 in the United States. E-58425 is an investigational medicinal product under development for the management of acute pain in adults that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate[1-9].
It has been a busy few weeks for drugmaker Esteve. No sooner did it unload a generics plant in Spain then it snapped up a specialty drug maker with a manufacturing facility in Germany.
It has been a busy few weeks for drugmaker Esteve. No sooner did it unload a generics plant in Spain then it snapped up a specialty drug maker with a manufacturing facility in Germany.
It has been a busy few weeks for drugmaker Esteve. No sooner did it unload a generics plant in Spain then it snapped up a specialty drug maker with a manufacturing facility in Germany.